AED
Evidence Grade E — Very limited evidence. 0 published studies. 0 registered clinical trials.
Cartalax is a synthetic tripeptide from the Khavinson bioregulator programme in Russia, proposed to target cartilage and connective tissue. No human clinical trials have been conducted and it has no regulatory approval. The evidence consists of cell culture studies from the originating research group.
No published studies found on PubMed.
Cartalax has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. The evidence base consists of cell culture studies published by the originating research group.
As with other Khavinson bioregulator peptides, the proposed tissue-targeting mechanisms have not been independently validated. Products available through unregulated channels lack pharmaceutical quality assurance.
Research from the Khavinson group proposes that Cartalax may bind DNA and modulate markers of cell proliferation, regeneration, and senescence in skin and kidney tissue cultures. These observations are from in vitro studies using immunofluorescent microscopy. The mechanisms derive from the Khavinson bioregulation framework.
Research suggests Cartalax has approximately 7 peer-reviewed publications showing effects across multiple cell types, making it one of the better-evidenced Khavinson peptides. The evidence shows a consistent mechanistic narrative. However, all studies originate from a single research group, no human clinical trials exist, and no independent Western replication has been published. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
TB-500 has no marketing authorisation from any regulatory agency. No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which are not pharmacologically equivalent. TB-500 is prohibited by WADA and is known from equine and greyhound racing contexts. Products available through unregulated channels lack pharmaceutical quality assurance. The absence of any human safety or efficacy data means that the compound's effects, risks, interactions, and appropriate dosing in humans are unknown.
ARA-290 (cibinetide) has no marketing authorisation. Phase II trials in sarcoidosis neuropathy showed improvements in corneal nerve fibre density, and a Phase II trial in diabetic neuropathy reported improved metabolic parameters and pain scores. The FDA granted Fast Track designation for sarcoidosis neuropathy. No Phase III trials have been completed. The compound represents an investigational approach to tissue repair that is distinct from existing erythropoietin-based therapies, but its clinical development remains at an early stage.
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment. No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
